Table 1 Basic characteristics of included studies in this meta-analysis
Study | Year | Country | Sample size | Age (year) Median(range) | Gender (M/F) | Study period | Study center | TNM stage | Treatment | Cut-off value | Cut-off value determination | Timing of FAR measurement | Survival endpoint | Follow-up (month) Median(range) | Survival analysis | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chen, S. | 2018 | China | 529 | 62(28–82) | 312/217 | 2010–2015 | Single center | I-III | Surgical resection | 0.103 | ROC curve | 1 month before surgery | OS, PFS | 35.0(1-78.5) | Multivariate | 8 |
Li, S. Q. | 2018 | China | 412 | 60.3 | 317/95 | 2005–2014 | Multicenter | I-IV | Mixed | 0.128 | X-tile | 7 days prior to treatment | OS | 1–36 | Multivariate | 9 |
Ying, J. | 2019 | China | 270 | 59.4 | 173/97 | 2011–2015 | Single center | III-IV | Chemotherapy | 0.125 | ROC curve | 1 day prior to chemotherapy | OS, PFS | 1–60 | Multivariate | 8 |
Zhao, X. | 2020 | China | 194 | 60(28–88) | 88/106 | 2016–2018 | Single center | I-IV | Targeted therapy | 0.08 | ROC curve | 7 days prior to treatment | OS, PFS | 1–60 | Multivariate | 8 |
Yuan, C. | 2022 | China | 91 | 61(32–80) | 68/23 | 2019–2021 | Single center | III-IV | Immunotherapy+ chemotherapy | 0.145 | ROC curve | Pretreatment | OS, PFS | 1–25 | Multivariate | 7 |
Huang, Q. | 2023 | China | 260 | ≤ 60y: 118 > 60y: 142 | 192/68 | 2017–2021 | Single center | III-IV | Chemotherapy | 0.119 | ROC curve | 7 days prior to treatment | OS, PFS | 1–60 | Univariate | 8 |
Ma, S. | 2024 | China | 899 | 61.4 | 413/486 | 2017–2021 | Single center | I-III | Surgical resection | 0.079 | ROC curve | Pretreatment | OS | 1–80 | Univariate | 8 |